Last reviewed · How we verify
Amoxicillin potassium clavulanate
Amoxicillin inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from degradation by bacterial beta-lactamases, extending its spectrum of activity.
Amoxicillin inhibits bacterial cell wall synthesis while clavulanic acid protects amoxicillin from degradation by bacterial beta-lactamases, extending its spectrum of activity. Used for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
At a glance
| Generic name | Amoxicillin potassium clavulanate |
|---|---|
| Also known as | 1000 mg amoxicillin and 200mg clavulanic acid., Augmentin, Amoxicillin-clavulanic acid, Amoxi-clav, Amoklavin |
| Sponsor | Kaizen Bioscience Co. |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that binds to penicillin-binding proteins and inhibits cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamases, preventing enzymatic degradation of amoxicillin and restoring its efficacy against beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reactions (including anaphylaxis)
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Collaborative Urological Prosthetics Investigation Directive Research Group (EARLY_PHASE1)
- Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amoxicillin potassium clavulanate CI brief — competitive landscape report
- Amoxicillin potassium clavulanate updates RSS · CI watch RSS
- Kaizen Bioscience Co. portfolio CI